Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies

The B cell surface antigen CD19 is a target for treating B cell malignancies, such as B cell precursor acute lymphoblastic leukemia and B cell non-Hodgkin lymphoma. The BiTE® immuno-oncology platform includes blinatumomab, which is approved for relapsed/refractory B cell precursor acute lymphoblasti...

Descripción completa

Detalles Bibliográficos
Autores principales: Viardot, Andreas, Locatelli, Franco, Stieglmaier, Julia, Zaman, Faraz, Jabbour, Elias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481145/
https://www.ncbi.nlm.nih.gov/pubmed/32856140
http://dx.doi.org/10.1007/s00277-020-04221-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481145/
https://www.ncbi.nlm.nih.gov/pubmed/32856140
http://dx.doi.org/10.1007/s00277-020-04221-0

Ejemplares similares